Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Mingot-Castellano, Maria E
58  Ergebnisse:
Personensuche X
?
1

Author Correction: Deciphering predictive factors for choic..:

Lozano, Maria L. ; Mingot-Castellano, Maria E. ; Perera, María M....
Scientific Reports.  11 (2021)  1 - p. , 2021
Link: https://doi.org/10.1038/..
 
?
2

A decade of changes in management of immune thrombocytopeni..:

Lozano, Maria L. ; Mingot-Castellano, Maria E. ; Perera, María M....
Blood Cells, Molecules, and Diseases.  86 (2021)  - p. 102505 , 2021
Link: https://doi.org/10.1016/..
 
?
3

Deciphering predictive factors for choice of thrombopoietin..:

Lozano, Maria L. ; Mingot-Castellano, Maria E. ; Perera, María M....
Scientific Reports.  9 (2019)  1 - p. , 2019
Link: https://doi.org/10.1038/..
 
?
4

Author Correction: Deciphering predictive factors for choic..:

Lozano, Maria L ; Mingot-Castellano, Maria E ; Perera, María M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363634/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
5

Incidence, characteristics and clinical profile of severe a..:

Mingot-Castellano, María E ; Alcalde-Mellado, Patricia ; Pascual-Izquierdo, Cristina...
http://hdl.handle.net/10668/17793.  , 2021
Link: http://hdl.handle.net/10..
 
?
6

A decade of changes in management of immune thrombocytopeni..:

Lozano, Maria L ; Mingot-Castellano, Maria E ; Perera, María M...
http://hdl.handle.net/10668/16322.  , 2020
Link: http://hdl.handle.net/10..
 
?
7

Deciphering predictive factors for choice of thrombopoietin..:

Lozano, Maria L ; Mingot-Castellano, Maria E ; Perera, María M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853922/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
?
8

Deciphering predictive factors for choice of thrombopoietin..:

Lozano, Maria L ; Mingot-Castellano, Maria E ; Perera, María M...
http://hdl.handle.net/10668/14687.  , 2019
Link: http://hdl.handle.net/10..
 
?
9

Real-world effectiveness of caplacizumab vs the standard of..:

Izquierdo, Cristina Pascual ; Mingot-Castellano, María Eva ; Fuentes, Ana E. Kerguelen...
Blood Advances.  6 (2022)  24 - p. 6219-6227 , 2022
Link: https://doi.org/10.1182/..
 
?
10

Use of eltrombopag after romiplostim in primary immune thro..:

González-Porras, José Ramón ; Mingot-Castellano, María Eva ; Andrade, Marcio M....
British Journal of Haematology.  169 (2014)  1 - p. 111-116 , 2014
Link: https://doi.org/10.1111/..
 
?
11

Consensus recommendations for the diagnosis and treatment o..:

Collins, Peter ; Baudo, Francesco ; Huth-Kühne, Angela...
BMC Research Notes.  3 (2010)  1 - p. , 2010
Link: https://doi.org/10.1186/..
 
?
12

Real-world effectiveness of caplacizumab vs the standard of..:

Izquierdo, Cristina Pascual ; Mingot-Castellano, María Eva ; Fuentes, Ana E. Kerguelen...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792393/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
13

Real-world effectiveness of caplacizumab vs the standard of..:

Pascual, Cristina ; Mingot-Castellano, María Eva ; Kerguelen Fuentes, Ana E...
Blood advances.  , 2022
Link: https://ddd.uab.cat/reco..
 
?
14

A decade of changes in management of immune thrombocytopeni..:

Lozano, Maria L ; Mingot-Castellano, M.E ; Perera, María M...
Blood Cells, Molecules, and Diseases;86.  , 2021
Link: https://hdl.handle.net/1..
 
?
15

Deciphering predictive factors for choice of thrombopoietin..:

Lozano, Maria L ; Mingot-Castellano, M.E ; Perera, María M...
Scientific Reports;9(1).  , 2019
Link: https://hdl.handle.net/1..
 
1-15